I don’t have the valuation model for LLY, but I thought that it might be interesting for you to see the value models for the other drug stocks I posted on earlier this week-end. There could be various reasons that the drug stocks are acting a little better than some of the other stocks. the health care debates have affected their overall performance, but valuation and dividend yield might be another factor in their individual performance. A look at the X dividend dates might also offer some insight as to price action.
Valuation models courtesy of www.powerinvestor.com
You must be logged in to post a comment.